Ginkgo Bioworks Secures $4.66M Contract to Enhance Microbial Research at EMSL with Automated Platform

Reuters
Yesterday
<a href="https://laohu8.com/S/DNA.WS">Ginkgo Bioworks</a> Secures $4.66M Contract to Enhance Microbial Research at EMSL with Automated Platform

Ginkgo Bioworks Holdings Inc., a leader in cell programming and biosecurity, has been awarded a $4.66 million contract to deliver an advanced automated anaerobic phenotyping platform to the Environmental Molecular Sciences Laboratory (EMSL) at Pacific Northwest National Laboratory. This system, based on Ginkgo's Reconfigurable Automation Cart $(RAC)$ technology, will consist of an integrated workcell with 18 devices housed within a modular anaerobic chamber. The platform will enable EMSL scientists to conduct complex end-to-end anaerobic phenotyping workflows remotely, enhancing research efficiency and accelerating discoveries in microbial engineering and bioeconomy science. This collaboration aims to strengthen U.S. leadership in biotechnology and bioeconomy research.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ginkgo Bioworks Holdings Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: NE40506) on July 30, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10